References
Aiuti A, Cattaneo F, Galimberti S, et al. (2009) Gene therapy for immunodeficiency due to adenosine deaminase deficiency. New England Journal of Medicine 360: 447–458.
Aiuti A, Biasco L, Scaramuzza S, et al. (2013) Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott‐Aldrich syndrome. Science 341: 1233151.
Aiuti A, Roncarolo MG and Naldini L (2017) Gene therapy for ADA‐SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Molecular Medicine 9: 737–740.
Biffi A, Montini E, Lorioli L, et al. (2013) Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341: 1233158.
Cai Y, Bak RO and Mikkelsen JG (2014) Targeted genome editing by lentiviral protein transduction of zinc‐finger and TAL‐effector nucleases. eLife 3: e01911.
Cartier N, Hacein‐Bey‐Abina S, Bartholomae CC, et al. (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X‐linked adrenoleukodystrophy. Science 326: 818–823.
Cattoglio C, Pellin D, Rizzi E, et al. (2010) High‐definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors. Blood 116: 5507–5517.
Cavazza A, Moiani A and Mavilio F (2013) Mechanisms of retroviral integration and mutagenesis. Human Gene Therapy 24: 119–131. DOI: 10.1089/hum.2012.203.
Cavazzana‐Calvo M, Payen E, Negre O, et al. (2010) Transfusion independence and HMGA2 activation after gene therapy of human beta‐thalassaemia. Nature 467: 318–322.
Cleveland SM, Smith S, Tripathi R, et al. (2013) Lmo2 induces hematopoietic stem cell‐like features in T‐cell progenitor cells prior to leukemia. Stem Cells 31: 882–894.
Davé UP, Akagi K, Tripathi R, et al. (2009) Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID‐X1 patients following retroviral gene therapy. PLoS Genetics 5: e1000491.
Fan H and Johnson C (2011) Insertional oncogenesis by non‐acute retroviruses: implications for gene therapy. Viruses 3: 398–422.
Finkelshtein D, Werman A, Novick D, et al. (2013) LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proceedings of the National Academy of Sciences of the United States of America 110: 7306–7311.
Ghosh S, Thrasher AJ and Gaspar HB (2015) Gene therapy for monogenic disorders of the bone marrow. British Journal of Haematology 171: 155–170.
Girard‐Gagnepain A, Amirache F, Costa C, et al. (2014) Baboon envelope pseudotyped LVs outperform VSV‐G‐LVs for gene transfer into early‐cytokine‐stimulated and resting HSCs. Blood 124: 1221–1231.
Hacein‐Bey‐Abina S, Von Kalle C, Schmidt M, et al. (2003) LMO2‐associated clonal T cell proliferation in two patients after gene therapy for SCID‐X1. Science 302: 415–419.
Hirsch T, Rothoeft T, Teig N, et al. (2017) Regeneration of the entire human epidermis using transgenic stem cells. Nature 551: 327–332.
Jinek M, Chylinski K, Fonfara I, et al. (2012) A programmable dual‐RNA‐guided DNA endonuclease in adaptive bacterial immunity. Science 337: 816–821.
Jinek M, East A, Cheng A, et al. (2013) RNA‐programmed genome editing in human cells. eLife 2: e00471.
Katzourakis A, Tristem M, Pybus OG and Gifford RJ (2007) Discovery and analysis of the first endogenous lentivirus. Proceedings of the National Academy of Sciences of the USA 104: 6261–6265.
Lévy C, Fusil F, Amirache F, et al. (2016) Baboon envelope pseudotyped lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell secretion in vivo in NOD/SCIDγc(‐/‐) mice. Journal of Thrombosis and Haemostasis 14: 2478–2492.
Lévy C, Amirache F, Girard‐Gagnepain A, et al. (2017) Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent. Blood Advances 24: 2088–2104.
Lombardo A, Genovese P, Beausejour CM, et al. (2007) Gene editing in human stem cells using zinc finger nucleases and integrase‐defective lentiviral vector delivery. Nature Biotechnology 25: 1298–1306.
Mali P, Yang L, Esvelt KM, et al. (2013) RNA‐guided human genome engineering via Cas9. Science 339: 823–826.
Noguchi P (2003) Risks and benefits of gene therapy. New England Journal of Medicine 348: 193–194.
Ortinski PI, O'Donovan B, Dong X and Kantor B (2017) Integrase‐deficient lentiviral vector as an all‐in‐One platform for highly efficient CRISPR/Cas9‐mediated gene editing. Molecular Therapy Methods and Clinical Development 5: 153–164.
Park JH, Geyer MB and Brentjens RJ (2016) CD19‐targeted CAR T‐cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 127: 3312–3320.
Senigl F, Auxt M and Hejnar J (2012) Transcriptional provirus silencing as a crosstalk of de novo DNA methylation and epigenomic features at the integration site. Nucleic Acids Research 40: 5298–5312.
Sessa M, Lorioli L, Fumagalli F, et al. (2016) Lentiviral haemopoietic stem‐cell gene therapy in early‐onset metachromatic leukodystrophy: an ad‐hoc analysis of a non‐randomised, open‐label, phase 1/2 trial. Lancet 388: 476–487.
Tobias A, Ahmed A, Moon KS and Lesniak MS (2013) The art of gene therapy for glioma: a review of the challenging road to the bedside. Journal of Neurology, Neurosurgery and Psychiatry 84: 213–222.
Zufferey R, Dull T, Mandel RJ, et al. (1998) Self‐inactivating lentivirus vector for safe and efficient in vivo gene delivery. Journal of Virology 72: 9873–9880.
Further Reading
Craigie R and Bushman FD (2014) Host factors in retroviral integration and the selection of integration target sites. Microbiology Spectrum 2 (6): MDNA3‐0026‐2014.
Ferrua F and Aiuti A (2017) Twenty‐five years of gene therapy for ADA‐SCID: from bubble babies to an approved drug. Human Gene Therapy 28: 972–981.
Kohn DB (2017) Historical perspective on the current renaissance for hematopoietic stem cell gene therapy. Hematology/Oncology Clinics of North America 31: 721–735.
Lévy C, Verhoeyen E and Cosset FL (2015) Surface engineering of lentiviral vectors for gene transfer into gene therapy target cells. Current Opinion in Pharmacology 24: 79–85.
Naldini L (2015) Gene therapy returns to centre stage. Nature 526: 351–360.
Pang Y, Hou X, Yang C, Liu Y and Jiang G (2018) Advances on chimeric antigen receptor‐modified T‐cell therapy for oncotherapy. Molecular Cancer 17: 91.
Skipper KA and Mikkelsen JG (2015) Delivering the goods for genome engineering and editing. Human Gene Therapy 26: 486–497.
Thrasher AJ and Williams DA (2017) Evolving gene therapy in primary immunodeficiency. Molecular Therapy 25: 1132–1141.